Programmed death ligand-1 expression in non-small cell lung cancer

Vamsidhar Velcheti, Kurt A. Schalper, Daniel E. Carvajal, Valsamo K. Anagnostou, Konstantinos N. Syrigos, Mario Sznol, Roy S. Herbst, Scott N. Gettinger, Lieping Chen, David L. Rimm

Research output: Contribution to journalArticlepeer-review

Abstract

Recent strategies targeting the interaction of the programmed cell death ligand-1 (PD-L1, B7-H1, CD274) with its receptor, PD-1, resulted in promising activity in early phase clinical trials. In this study, we used various antibodies and in situ mRNA hybridization to measure PD-L1 in non-small cell lung cancer (NSCLC) using a quantitative fluorescence (QIF) approach to determine the frequency of expression and prognostic value in two independent populations. A control tissue microarray (TMA) was constructed using PD-L1-transfected cells, normal human placenta and known PD-L1-positive NSCLC cases. Only one of four antibodies against PD-L1 (5H1) validated for specificity on this TMA. In situ PD-L1 mRNA using the RNAscope method was similarly validated. Two cohorts of NSCLC cases in TMAs including 340 cases from hospitals in Greece and 204 cases from Yale University were assessed. Tumors showed PD-L1 protein expression in 36% (Greek) and 25% (Yale) of the cases. PD-L1 expression was significantly associated with tumor-infiltrating lymphocytes in both cohorts. Patients with PD-L1 (both protein and mRNA) expression above the detection threshold showed statistically significant better outcome in both series (log-rank P=0.036 and P=0.027). Multivariate analysis showed that PD-L1 expression was significantly associated with better outcome independent of histology. Measurement of PD-L1 requires specific conditions and some commercial antibodies show lack of specificity. Expression of PD-L1 protein or mRNA is associated with better outcome. Further studies are required to determine the value of this marker in prognosis and prediction of response to treatments targeting this pathway.

Original languageEnglish (US)
Pages (from-to)107-116
Number of pages10
JournalLaboratory Investigation
Volume94
Issue number1
DOIs
StatePublished - Jan 2014
Externally publishedYes

Keywords

  • NSCLC
  • PD-L1
  • survival
  • tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Programmed death ligand-1 expression in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this